|Day Low/High||0.06 / 0.08|
|52 Wk Low/High||0.01 / 0.20|
OTC-QB listing becomes effective at opening of trading on December 19, 2017
Oncolix CEO Michael Redman tells TheStreet how his firm is extending lives by developing treatment for women's cancers. Here's what their biotech innovation has coming down the pipeline.
OTC-QB listing anticipated to be finalized before the end of the year
OTC-QB requirements are fulfilled with two independent board members appointed
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.